Retraction Retraction dated 2024-02-13
Click to view Retraction: https://doi.org/10.1007/s00705-024-05990-z
-
Authors
Said, Ebada Mohamed
Abdulaziz, Badawy A.
El Kassas, Mohamed
El Attar, Ibrahim Hussein
Emadeldeen, Mohammed
Abd-Elsalam, Sherief M. https://orcid.org/0000-0003-4366-2218
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02992457 at ClinicalTrials.govDocuments that mention this clinical trial
RETRACTED ARTICLE: High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir therapy: a real-life experience
https://doi.org/10.1007/s00705-020-04639-x
- License Information
-
More Information
Article History
Received: 25 January 2020
Accepted: 31 March 2020
First Online: 30 April 2020
Change Date: 28 August 2023
Change Type: Update
Change Details: Editor's Note: Readers are alerted that concerns have been raised about the reporting of this clinical trial. Further editorial action will be taken as appropriate once the investigation into the concerns is complete and all parties have been given an opportunity to respond in full.
Change Date: 13 February 2024
Change Type: Correction
Change Details: This article has been retracted. Please see the Retraction Notice for more detail:
Change Details: https://doi.org/10.1007/s00705-024-05990-z
Compliance with ethical standards
:
: :The authors declare that there is no conflict of interest.
: Participants provided written informed consent, and the study was approved by the institutional ethical committee.
